Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.65 GBX | -3.70% | -10.34% | -23.53% |
Feb. 15 | N4 Pharma's In-vitro Study Shows Nuvec's Versatility in Inhibiting Cancer Cells | MT |
Feb. 15 | N4 Pharma shares rise on "encouraging" Nuvec research | AN |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.32M 5.45M |
---|---|---|---|---|---|
Net income 2021 | -1M -1.26M | Net income 2022 | -1M -1.26M | EV / Sales 2021 | - |
Net cash position 2021 | 1.78M 2.25M | Net cash position 2022 | 1.92M 2.42M | EV / Sales 2022 | - |
P/E ratio 2021 |
-5.22
x | P/E ratio 2022 |
-3.35
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 87.14% |
Latest transcript on N4 Pharma Plc
1 day | +11.11% | ||
1 week | +15.38% | ||
Current month | +7.14% | ||
1 month | +7.14% | ||
3 months | -16.67% | ||
6 months | -25.00% | ||
Current year | -11.76% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.65 | -3.70% | 1,668,891 |
24-03-27 | 0.675 | 0.00% | 580,163 |
24-03-26 | 0.675 | 0.00% | 523,124 |
24-03-25 | 0.675 | -5.46% | 498,899 |
24-03-22 | 0.714 | +9.85% | 512,267 |
Delayed Quote London S.E., March 28, 2024 at 04:56 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-11.76% | 2.29M | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.72% | 210B | |
+1.32% | 210B | |
-6.75% | 201B | |
-3.51% | 157B |